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Abstract 
Aims/hypothesis: Metabolic disorders are commonly investigated using knockout and transgenic mouse 
models. A variety of mouse strains have been used for this purpose. However, mouse strains can differ in 
their inherent propensities to develop metabolic disease, which may affect the experimental outcomes of 
metabolic studies. We have investigated strain-dependent differences in the susceptibility to diet-induced 
obesity and insulin resistance in five commonly used inbred mouse strains (C57BL/6J, 129X1/SvJ, BALB/
c, DBA/2 and FVB/N). Methods: Mice were fed either a low-fat or a high-fat diet (HFD) for 8 weeks. Whole-
body energy expenditure and body composition were then determined. Tissues were used to measure 
markers of mitochondrial metabolism, inflammation, oxidative stress and lipid accumulation. Results: 
BL6, 129X1, DBA/2 and FVB/N mice were all susceptible to varying degrees to HFD-induced obesity, 
glucose intolerance and insulin resistance, but BALB/c mice exhibited some protection from these 
detrimental effects. This protection could not be explained by differences in mitochondrial metabolism or 
oxidative stress in liver or muscle, or inflammation in adipose tissue. Interestingly, in contrast with the 
other strains, BALB/c mice did not accumulate excess lipid (triacylglycerols and diacylglycerols) in the 
liver; this is potentially related to lower fatty acid uptake rather than differences in lipogenesis or lipid 
oxidation. Conclusions/interpretation: Collectively, our findings indicate that most mouse strains develop 
metabolic defects on an HFD. However, there are inherent differences between strains, and thus the 
genetic background needs to be considered carefully in metabolic studies. 
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Abstract 
Metabolic disorders are commonly investigated using knockout and transgenic mouse 
models. A variety of mouse strains have been used for this purpose. However, mouse strains 
differ in their inherent propensities to develop metabolic disease, and this may affect the 
experimental outcomes of metabolic studies. We have investigated strain-dependent 
differences in the susceptibility to diet-induced obesity and insulin resistance in five 
commonly used mouse strains (C57BL/6J, 129X1/SvJ, BALB/c, DBA/2 and FVB/N). BL6, 
129X1, DBA/2 and FVB/N mice were all susceptible to varying degrees to high-fat diet 
(HFD)-induced obesity, glucose intolerance and insulin resistance, but BALB/c exhibited 
some protection from the detrimental effects of a HFD. This protection could not be 
explained by differences in mitochondrial metabolism or oxidative stress in liver or muscle or 
inflammation in adipose tissue. Interestingly BALB/c mice were the only strain that did not 
accumulate excess lipid in the liver, which may be related to lower fatty acid uptake rather 
than differences in lipogenesis or lipid oxidation. Collectively, our findings indicate that aside 
from the BALB/c strain, the other mouse strains examined in this study are all suitable 
models for investigating metabolic defects induced by dietary lipid oversupply. 
Introduction 
In the past 30 years, the use of transgenic and knockout mouse strains to investigate the role 
of a specific protein in metabolic disease has become common place in medical research. 
However, when creating a genetically-manipulated mouse model, consideration must be 
given to the genetic background on which the mouse is created and the differences in 
metabolic phenotype that might be associated with investigating gene manipulation on mixed 
genetic backgrounds. Several previous studies have shown that mouse strains can differ 
substantially in their metabolic phenotype under normal low-fat diet conditions and in 
response to a high fat diet (1-3). Problems with these and other previous strain comparisons 
are the use of diverse high-fat diets varying in lipid and carbohydrate content, the 
investigation of limited parameters that may underpin the development of metabolic disease 
and importantly some contradictory findings. For example, FVB/N mice have been 
previously characterized as obesity-prone (4) or obesity-resistant (3), and similar 
contradictory observations have been reported for DBA/2 mice (1; 5).  
The C57BL/6 mouse strain is generally suggested to be the best strain for studying 
metabolic disease. However, it is worth noting that BL6 mice have also been described as 
“diabetes-prone” or “diabetes-resistant” depending on which other mouse strain was used in 
the comparison (6). The preference for the use of C57BL/6 mice probably stems from studies 
where it was shown that a high-fat and high-sucrose diet caused a 50% increase in fasting 
glucose and a 10-fold increase in plasma insulin levels (7), demonstrating obesity-induced 
insulin resistance in this particular strain. The susceptibility of C57BL/6 mice to develop 
glucose intolerance was later shown to be to some extent due to impaired insulin secretion (8; 
9). Because of the utility of using 129X1/SvJ mouse embryonic stem cells for the generation 
of gene manipulated strains, much of the original metabolic phenotyping in knockout and 
transgenic mice was performed using mice produced on this strain or more frequently using 
mice backcrossed to C57BL/6 for a defined or undefined number of generations (10). There 
is however clear evidence that genetically manipulated mice on a mixed 129/BL6 can display 
different phenotype to mice where the same genetic manipulation is performed on a pure 
genetic background (11).   
A number of mechanisms have been proposed to be responsible for obesity-related 
insulin resistance, lipid accumulation in non-adipose tissues, inflammation in adipose and 
other tissues, mitochondrial dysfunction, and/or oxidative stress. Much of the evidence 
supporting these various theories is based on studies in normal or genetically manipulated 
mice fed high-fat diets, however it is still not completely resolved to what extent these factors 
may be related to the genetic background of mice. Here, we report studies on the response of 
five commonly used mouse strains (C57BL/6, 129X1/SvJ, BALB/c, DBA/2 and FVB/N) to 
the same high-fat diet, examining glucose tolerance, whole-body and tissue-specific lipid 
accumulation, and aspects of tissue inflammation, mitochondrial function and oxidative 
stress.  
Research design and methods 
Eight-week old C57BL/6J, 129X1/SvJ, BALB/c, DBA/2 and FVB/N mice were purchased 
from the Australian Resource Centre (Perth, Australia). Mice were housed with 4 animals per 
cage in a temperature-controlled room (22°C ± 1°C) with a 12-hour light/dark cycle and ad 
libitum access to food and water. After one week on a standard low-fat laboratory diet (low 
fat; 8% calories from fat, 21% calories from protein, 71% calories from carbohydrate; 
Gordon’s Specialty Stock Feeds, Yanderra, NSW, Australia), mice from each strain were 
randomly allocated to remain on the low-fat diet (LFD) or to receive a high-fat diet (HFD) ad 
libitum for 8 weeks. The HFD was made in-house (12) and is based on rodent diet no. 
D12451 (containing 45% of calories from lard) (Research Diets, New Brunswick, NJ). 
During the 8-week feeding period, body weight and food intake was monitored on a bi-
weekly basis. As all mice were kept in cages of 4 animals, food intake per cage was averaged 
and is expressed in kJ/mouse/day. All experiments were carried out with the approval of the 
Garvan Institute/St. Vincent’s Hospital Animal Experimentation Ethics Committee, following 
guidelines issued by the National Health and Medical Research Council of Australia. 
Determination of body composition and energy expenditure.  
Fat and lean body mass were measured in mice using dual-energy X-ray absorptiometry 
(DXA) (Lunar PIXImus2 mouse densitometer; GE Healthcare) in accordance with the 
manufacturer’s instructions. Oxygen consumption rate (VO2) and respiratory control ratio 
(RER) of individual mice was measured using an eight-chamber indirect calorimeter 
(Oxymax series; Columbus Instruments, Columbus, OH) as previously described (13). 
In vivo glucose tolerance. 
Mice were fasted for 6 hours (from 8am) and then injected intraperitoneally with glucose (2 
g/kg) or insulin (0.75 U/kg), and blood glucose levels were monitored over time using an 
Accu-check II glucometer (Roche Diagnostics, Castle Hill, Australia). During the glucose 
tolerance test some samples were collected for plasma insulin determination by 
radioimmunoassay using a rat-specific kit (Linco Research, St. Charles, MO).  
Palmitate oxidation. 
Palmitate oxidation was measured in muscle and liver homogenates as described previously 
(13). CO2 produced during the incubation was collected in 100 μl of 1 M sodium hydroxide. 
14C counts present in the acid-soluble fraction were also measured and combined with the 
CO2 values to give the total palmitate oxidation rate. Protein content in the homogenates was 
measured using the Bradford method (protein assay kit; Bio-Rad Laboratories, Regents Park, 
Australia). 
 
Tissue lipid analyses. 
Lipids were extracted from tissues by standard methods (14). Plasma, muscle and liver 
triglyceride contents were determined using a colorimetric assay kit (Triglycerides GPO-
PAP; Roche Diagnostics, Indianapolis, IN) as previously described (15). Similarly, plasma 
NEFAs were measured using a colorimetric kit (WAKO diagnostics, Osaka, Japan). Full 
details of the methods for diacyglycerol (DAG) and ceramide measurements can be found in 
the Supplementary file. Briefly, lipids were extracted from muscle and liver in solvents 
containing 2 nmoles of ceramide (17:0) and 10 nmoles of DAG (17:0/17:0). DAG and 
ceramide levels were measured using a hybrid linear ion trap-triple quadrupole mass 
spectrometer (QTRAP® 5500, ABSCIEX, Foster City, CA, USA) and data were analyzed 
with LipidView® (ABSCIEX) version 1.1.  
SDS-PAGE and immunoblotting. 
Whole-tissue lysates were prepared from powdered muscle and liver by manual 
homogenization in RIPA buffer (16) followed by incubation for 2 hours at 4 °C and 
centrifugation for 10 min at 12,000 g. Protein content of supernatants was quantified using 
the Bradford method. 20 µg of protein were denatured in Laemmli buffer for 15min at 65 °C 
and then resolved by SDS-PAGE electrophoresis (Invitrogen). Protein was electrotransferred 
onto polyvinylidine difluoride membranes, immunoblotted and quantitated, as described 
previously (17). Detailed information on immunoblotting can be found in the Supplementary 
file. 
Enzyme activity measurements. 
Muscle and liver samples were manually homogenized 1:8 (wt/vol) in 50 mM Tris-HCl, 1 
mM EDTA and 0.1% Triton X-100, pH 7.2, followed by centrifugation for 10 min at 5,000 g. 
Supernatants were used to determine citrate synthase (CS) and β-hydroxyacyl CoA 
dehydrogenase (βHAD) activity at 30 °C as described previously (13) using a temperature-
controlled spectrophotometer (Spectra Max 250, Molecular Devices, Sunnyvale, CA). 
Glutathione peroxidase (GPx) activity was determined as the decrease in NADPH absorption 
at 340 nm and 30 °C, as described previously (18).  
 
 
Gene expression analysis. 
RNA was extracted using TRI-Reagent (Sigma-Aldrich) according to the manufacturer’s 
protocol, followed by DNAse treatment (RQ1 RNase-free DNase, Promega) and synthesis of 
complementary DNA using Random primer 9 (New England Biolabs) and Superscript III 
reverse transcriptase (Invitrogen) according to the manufacturer’s instructions. Real-time 
PCR was performed using the Lightcycler® 480 Probes Master mix on a real-time PCR 
System (7900HT; Applied Biosystems). The value obtained for each specific product was 
normalised to a control gene (Hypoxanthine-guanine phosphoribosyltransferase) and the 
results are expressed as fold-change of the HFD-fed mice vs. the LFD-fed mice for each 
strain. Primer sequences are shown in Supplementary Table 1.  
Oxidative damage biomarkers. 
Muscle and liver samples were homogenized as described above for the enzyme activity 
measures. TBARS were determined, as described previously (19). For the determination of 
protein carbonylation, nucleic acids were removed using 1% streptomycin (incubation at 
room temperature for 15 min, followed by centrifugation at 6000 g, 10 min, 4 °C) (20), and 
the supernatant used for the assay. Protein carbonyls were derivatized to 2,4-
dinitrophenylhydrazone by reaction with 2,4-dinitrophenylhydrazine (DNPH) as described 
previously (21). Lipid hydroperoxides (LOOH) were measured using the FOX2-Assay, as 
described previously (22).  
Statistical analysis 
Data analysis was performed using JMP 5.1 (Statistical Analysis System Institute Inc., Cary, 
NC, USA). All results are given as mean ± standard error with n being the number of animals 
used in each assay and P = 0.05 set as the level of significance. Data were tested for 
normality using the Shapiro–Wilk W test and homogeneity of variance using the O’Brien and 
Brown-Forsythe tests. Data not normally distributed were compared using non-parametric 
Wilcoxon/Kruskal–Wallis tests and any data showing unequal variance were compared using 
a Welch ANOVA. For each mouse strain, a one-way ANOVA was completed with low-fat or 
high-fat diet as the independent variable and the measured metabolic parameters as dependent 
variables. Means were then compared using the Tukey–Kramer honestly significant 
difference test.  
Results 
Body weight, fat mass and food intake during high-fat feeding 
Compared to animals remaining on a LF diet, body weight was significantly increased in Bl6, 
129X1, DBA/2 and FVB/N mice fed the high-fat, but remained unchanged in BALB/c mice. 
High-fat fed DBA/2 and 129X1 mice showed the largest increase in body weight in 
comparison to all other strains (25 % increase for both strains) (Fig. 1A). Whole-body 
adiposity measured by dual-energy X-ray absorptiometry was increased in all five mouse 
strains on the HFD, including the BALB/c mice, as was the size of the epididymal and 
inguinal fat depots (Table 1).  
Food intake was measured bi-weekly as an average of 2 cages with 4 animals per cage for 
each mouse strain. The energy intake (shown in kJ/day) during the 8-week feeding period 
was higher in HFD-fed 129X1 and DBA/2 mice compared to LF controls, but was not 
significantly different in BL6, BALB/c and FVB/N mice (Table 1). 
Whole-animal respiration and fuel selection, as well as tissue-specific lipid oxidation 
Whole-animal oxygen consumption, corrected for lean mass (as determined by DXA), was 
significantly increased to a similar extent in all mouse strains on the HFD (11-16% increase). 
Similarly, the respiratory exchange ratio (RER) was significantly decreased in all five strains 
consistent with increased lipid intake and catabolism (Table 1).   
Glucose tolerance and insulin sensitivity 
To determine the effect of HFD on whole-body glucose metabolism, we examined glucose 
clearance during an intraperitoneal glucose tolerance test (ipGTT) (Fig. 1B). In four of the 
mouse strains, the HFD-fed animals displayed a significant impairment in glucose tolerance, 
demonstrated by a substantial increase in the incremental glucose area under the curve (AUC) 
(BL6 +97%, 129X1 +284%, DBA/2: +130%, FVB/N +37%). In contrast, BALB/c mice 
exhibited no deterioration in glucose tolerance on the HFD, (AUC: -0.6% vs. LFD).  
To examine the insulin response to elevated blood glucose levels, we measured insulin levels 
during the ipGTT (Suppl. Fig. 1). Despite all five mouse strains (particularly DBA/2) having 
higher insulin levels during the ipGTT when on the HFD in comparison to their LFD-
counterparts, BALB/c mice on the HFD had the lowest plasma insulin levels for all time 
points during the GTT in comparison to all other HFD-fed mouse strains (see Table 2 for 
fasting insulin = zero time point during GTT). Similarly, fasting blood glucose and fasting 
plasma insulin were significantly increased in all mouse strains on the HFD except for 
BALB/c (Table 2). As an indicator of insulin sensitivity, ‘fasting glucose’ was multiplied by 
‘fasting insulin’ and is presented as an Insulin Sensitivity Index (ISI) for each diet group and 
mouse strain. The ISI demonstrated substantial impairment in insulin sensitivity in all mouse 
strains, except the BALB/c (increase in ISI value vs. LFD group: BL6 +96%, 129X1 +128%, 
BALB/c: +4%, DBA/2: +234%, FVB/N +70%). An intraperitoneal insulin tolerance test 
(ipITT) was used as a second measure of insulin sensitivity (Suppl. Fig. 2). Similarly to the 
ISI, the AUC for the ipITT indicated the development of insulin resistance in all high-fat fed 
mouse strains, except BALB/c (increase in AUC values vs. LFD group: BL6 +22%, 129X1 
+16%, BALB/c: -8%, DBA/2: +56%, FVB/N +39%).  
Lipid accumulation in non-adipose tissues 
Due to the well-established link between insulin resistance and intracellular lipid 
accumulation in non-adipose tissues (23), we examined lipid accumulation in quadriceps 
muscle and liver of all LF- and HF-fed mice. All HF-fed mouse strains showed an increased 
triglyceride deposition in their muscles, while only the FVB/N strain also displayed elevated 
DAG and ceramide content (Fig 2). In the liver, triglyceride and DAG levels were 
significantly increased in BL6, 129X1, DBA/2 and FVB/N mice, with a decreased ceramide 
level also observed in liver from BL6 mice. Intriguingly, HF-fed BALB/c mice did not 
accumulate any excess triglyceride or DAG in their livers compared to LF controls, and also 
displayed a 25% reduction in ceramide levels (Fig. 2).  
Markers of mitochondrial oxidative metabolism in liver and skeletal muscle 
Causative links have been proposed between mitochondrial dysfunction and intracellular lipid 
accumulation and insulin resistance (24). To determine if insulin resistance and lipid 
accumulation in BL6, 129X1, DBA/2 and FVB/N mice on the HFD was accompanied by 
differences in mitochondrial fuel utilization, and to identify if the absence of lipid 
accumulation in BALB/c liver was due to an increase in mitochondrial oxidation, we have 
examined several markers of mitochondrial metabolism.  
Figures 3 and 4 show representative immunoblotting analysis of a variety of markers of 
mitochondrial metabolism. In skeletal muscle, there was a significant increase in PGC1α, 
UCP3, PDK4 and sub-units of the complexes of the electron transport chain (ETC) in all 
mouse strains on the HFD, except the BALB/c (for details in percentage changes refer to Fig. 
3A). In BALB/c muscle, mitochondrial proteins were either unchanged or decreased in the 
HFD-fed animals. A similar trend was observed with citrate synthase (CS) and β-hydroxyacyl 
CoA dehydrogenase (βHAD) activity in skeletal muscle, with BALB/c being the only strain 
that showed no increase in these enzyme activities on the HFD (Fig. 3B and 3C). 
Furthermore, to determine the effect of HFD on fatty acid oxidative capacity, we measured 
the rate of palmitate oxidation in muscle and liver. Skeletal muscle from fat-fed mice from all 
mouse strains, including the BALB/c mice, displayed an increased capacity for palmitate 
oxidation (Suppl. Fig. 4). Although there was a slight increase in fatty acid oxidation in 
BALB/c muscle, the collective findings suggest, that a HFD in Bl6, 129X1, DBA/2 and 
FVB/N mice leads to stimulation of mitochondrial oxidative pathways, whereas BALB/c 
mice show little change in the same skeletal muscle parameters in response to the HFD.  
In the liver, CS and βHAD enzymatic activity was significantly increased in 129X1, DBA/2 
and FVB/N mice, but not in BL6 and BALB/c mice (Suppl. Fig. 3). Western blot analysis in 
the liver showed a significant increase in PGC1α, CPT1 and complex II of the ETC in high-
fat fed BL6 mice, a decrease in a variety of mitochondrial markers in FVB/N mice, and no 
change in any other strain (Fig. 4). Furthermore, the palmitate oxidation rate, used as a 
marker of fatty acid oxidative capacity of the liver, was unchanged on the HFD in all mouse 
strains (Suppl. Fig. 4). These findings suggest that the absence of lipid accumulation in liver 
of HFD BALB/c mice is not due to an increase in mitochondrial lipid utilization.   
Lipid synthesis and uptake in the liver 
Because BALB/c mice did not accumulate liver lipid on a HFD and did not exhibit increased 
mitochondrial oxidative capacity, we examined the protein expression of several markers of 
lipogenesis and fatty acid uptake into the liver. The protein expression of FAS, ACC and 
SCD-1 was decreased in all strains except the DBA/2 which showed unchanged FAS and 
SCD-1 levels and an increased ACC protein expression on the HFD (Fig. 4). High-fat fed 
BALB/c mice showed a similar reduction in lipogenesis as other mouse strains, suggesting 
that a decrease in lipogenic capacity could not explain the lower liver lipid content in 
BALB/c mice.  
Furthermore, we measured protein expression of the major hepatic fatty acid transport 
proteins (FATP) 2 and 4 as markers of fatty acid uptake into the liver. High-fat fed BALB/c 
and BL6 mice were the only strains that did not show a consistent increase in liver fatty acid 
transport proteins in comparison to their LFD-counterparts. In fat-fed BALB/c mice, protein 
expression of FATP2 remained unchanged, whereas FATP4 was even lower compared to the 
LFD-fed mice (Fig. 4). These results suggest that lipid accumulation in BALB/c liver on a 
HFD might be limited by a reduced capacity for fatty acid uptake. 
Diet-induced changes in inflammation in adipose tissue and liver 
The reduced insulin action associated with diet-induced obesity has been frequently linked to 
increased inflammation in adipose and other tissues. To determine if differences in glucose 
tolerance and insulin resistance in the mouse strains was associated with macrophage 
infiltration in adipose tissue, we examined the gene expression of F4/80, CD68 and CD11c+, 
which are surface markers of M1- and M2-macrophages, as well as TNFα, MCP-1 and IL-6 
as markers of cytokine production by macrophages and adipocytes. F4/80, CD68 and CD11c+ 
increased in adipose tissue of all HFD-fed mouse strains (Fig. 5), indicating that leukocyte 
and macrophage infiltration into adipose tissue is already present after 8 weeks of high-fat 
feeding in all mouse strains including BALB/c mice (Fig. 5 A-C). Interestingly, increased 
TNFα, MCP-1 and IL-6 mRNA levels were only present in BALB/c, DBA/2 and FVB/N 
mice, demonstrating that not all strains respond to increased macrophage infiltration with 
increased cytokine expression after 8 weeks on the HFD (Fig. 5 D-F). Together, the gene 
expression analysis does not support adipose tissue inflammation as a major reason for the 
different glucose handling observed in HFD-fed BALB/c mice. In addition, we have 
measured protein expression of JNK, IKKα and IKKβ, IκB (total and phosphorylated for all 
except IκB) as markers of liver inflammation in the liver of LFD- and HFD mice  and found 
no changes in any liver inflammation marker after 8 weeks of high-fat feeding (data not 
shown).  
Diet-induced oxidative stress: Antioxidant protection & Oxidative damage 
To determine if lipid accumulation in muscle and liver correlates with oxidative damage to 
lipids and to examine if lower oxidative stress levels could partly explain the differences 
observed in BALB/c mice, we measured lipid hydroperoxides (LOOH) and TBARS 
(thiobarbituric acid reactive substances) in those two tissues. In muscle, LOOH and TBARS 
levels were significantly decreased in BALB/c mice on the HFD whereas there was a trend to 
increased oxidative damage in the other strains. (Fig. 6 A+B). In the liver however, HFD 
BALB/c mice were the only strain that displayed increased lip-oxidative damage compared to 
LFD-counterparts (Fig. 6 C+D). In addition to lower LOOH and TBARS levels in muscle of 
HFD BALB/c mice, protein carbonylation and glutathione peroxidase (GPx) activity were 
also significantly decreased (Suppl. Fig. 5), suggesting decreased oxidative stress in muscle 
of HFD BALB/c mice, but not in the other mouse strains. Low oxidative stress in skeletal 
muscle, but not in the liver, might be one of the mechanisms responsible to the lack of 
glucose intolerance and insulin resistance observed in BALB/c mice fed the HFD.  
Discussion 
The data obtained in this study gives a clear indication of the similarities and differences in a 
number of metabolic parameters in five commonly used mouse strains in response to eight 
weeks of feeding with a HFD. On a HFD all strains of mice gained a significant amount of 
body fat. All strains except BALB/c also exhibited a significant but variable deterioration in 
glucose tolerance. Intriguingly BALB/c mice maintained normal glucose tolerance despite 
increased adiposity, increased muscle triglyceride accumulation, oxidative stress in liver and 
elevated levels of adipose tissue inflammation. This is somewhat surprising because increases 
in all these parameters have previously been suggested to be key abnormalities predisposing 
to insulin resistance and increasing the risk of developing type 2 Diabetes. The most obvious 
difference in BALB/c mice that might explain their ability to maintain glucose tolerance on a 
HFD was the lack of lipid accumulation in liver in this strain. All other strains had significant 
accumulation of triglycerides and DAGs in liver on the HFD and significant glucose 
intolerance. 
Lipid accumulation in non-adipose tissues has been shown to be closely related to the 
development of glucose intolerance and insulin resistance (23; 25). In the current study 
BALB/c mice displayed a similar pattern of lipid accumulation in muscle to the other four 
mouse strains. This suggests that in the current investigation muscle lipid accumulation was 
not a major determinant of glucose tolerance across the different strains. Intriguingly, fat-fed 
BALB/c mice did display a disparate lipid profile to the other strains in the liver, with no 
excess triglyceride or DAG accumulation and a reduced ceramide content. This difference in 
liver lipid accumulation may partly explain the maintained glucose tolerance and insulin 
action in the BALB/c mice fed a HFD and is potentially due to lower rates of fatty acid 
uptake in BALB/c liver. In BALB/c, the expression of FATP2 and FATP4, which are the 
most abundant fatty acid transporters expressed in the liver (26), remained either unchanged 
(FATP2) or was decreased (FATP4) whereas in most other strains the amount of these 
transporters increased when fed a HFD. The BALB/c mice phenotype of increased fat mass 
but normal glucose tolerance seems similar to the recently described metabolically healthy 
obese (MHO) humans. MHO humans, despite having severe adiposity, remain relatively 
insulin sensitive, as indicated by HOMA-IR and euglycaemic-hyperinsulinemic clamps (27). 
Interestingly, one of the observed metabolic differences between MHO and obese insulin-
resistant humans was liver lipid content, with the metabolically-healthy obese individuals 
displaying low liver lipid accumulation, despite visceral adiposity (28). Obesity in BALB/c 
mice might well provide an opportunity to further investigate the links between lipid 
metabolism in liver and glucose tolerance. 
Each of the five mouse strains examined exhibited defined but different physiological 
responses to a high-fat diet. This difference in metabolic response was clearly apparent when 
comparing the GTT curves. Although HFD-fed BL6, 129X1, DBA2 and FVB/N mice all 
became glucose intolerant, the response of each strain to a glucose bolus differed 
substantially, both on low-fat and high-fat diets. For example, FVB/N mice on a standard 
LFD are relatively glucose intolerant in comparison to the other strains, and have similar 
glucose tolerance to BL6 mice on a HFD. BL6 mice are the most common mouse strain used 
in the study of metabolic disease, as they have been suggested to be the most susceptible to 
the development of diet-induced obesity and insulin resistance. In the present investigation 
BL6 mice displayed intermediate adiposity, insulin resistance and lipid accumulation in 
muscle and liver when compared to the other four mouse strains investigated. The strain that 
accumulated the most fat (37% of total body weight) and exhibited the greatest glucose 
intolerance on a HFD (3-fold increase in AUC) was the 129X1 strain. A large number of 
genetically manipulated mice are produced on the 129X1 background and then backcrossed 
to BL6 for varying generations. The clear difference in glucose tolerance and other metabolic 
parameters between BL6 and 129X1 suggest it is extremely important to know the extent of a 
mixed background in genetically manipulated mice before drawing conclusions about the 
influence of a specific gene on metabolic homeostasis.  
DBA/2 mice also displayed an interesting response to a high-fat diet. Although DBA/2 show 
the largest increase in body weight and also gained substantial amounts of fat mass, they 
become only marginally glucose intolerant on the HFD. DBA/2 exhibited similar differences 
in lipid accumulation, mitochondrial metabolism, inflammation and oxidative stress to other 
strains, however, DBA/2 mice did exhibit a large increase in fasting insulin, and the largest 
excursion of plasma insulin levels during the glucose tolerance test, suggesting that it is 
compensatory hyperinsulinemia that reduces HFD-induced glucose intolerance in this strain 
(1; 8).  
Mitochondrial dysfunction, oxidative stress and inflammation are commonly suggested as 
mediators of insulin resistance and glucose intolerance in obese animal models and obese 
humans (23; 24). In the current study all the of the mouse strains (except BALB/c) responded 
to a HFD as BL6 mice did in our previous study, with a modest increase in the expression, as 
well as activity of mitochondrial proteins, and an increase in capacity to oxidize fatty acids 
(13). BALB/c mice were the only mouse strain where mitochondrial oxidative capacity 
remained unchanged (enzyme activities) or was even decreased (protein expression) in high-
fat fed animals and glucose tolerance was preserved in this strain. These results suggest the 
HFD-induced changes in muscle mitochondrial capacity do not correlate with glucose 
tolerance in these mouse strains. Oxidative stress in liver and muscle of all strains was also 
assessed by examining levels of lipid hydroperoxides and TBARS. The only consistent effect 
was that HFD increased markers of lipid peroxidation in liver of BALB/c mice, but decreased 
these markers in muscle of the same animals, which again is difficult to reconcile against the 
observation that BALB/c mice maintain normal glucose tolerance and insulin action on a 
HFD. Investigation of the inflammatory state of adipose tissue in the different strains of 
HFD-fed mice, produced substantial evidence of macrophage infiltration (increased F4/80 
and CD11c gene expression) in all strains and evidence of increased cytokine expression 
(TNF and MCP-1) in 3 of the 5 strains including BALB/c. These results demonstrate that 
adipose tissue inflammation can be observed within 8 weeks of a HFD, even in the presence 
of normal glucose tolerance and insulin action in BALB/c mice, and thus support the notion 
that inflammation may only contribute to glucose tolerance and insulin action after long-term 
high fat feeding (29; 30). 
Altogether, this extensive comparison of the effects of a HFD on different mouse strains 
demonstrates that all strains accumulate body fat and show signs of adipose tissue 
inflammation and muscle lipid accumulation. However, the effect of fat accumulation on 
markers of glucose homeostasis is variable and strain dependent. In particular, BALB/c mice 
remain glucose tolerant on a HFD and this seems directly related to the lack of accumulation 
of fat in liver of these mice, despite lipid accumulation in muscle. The results suggest that 
liver lipid content is a major determinant of glucose tolerance and also highlight the need for 
caution when comparing results of dietary interventions in studies involving different or 
mixed strains of mice. 
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Table 1: Animal characteristics, including tissue weights, food intake and whole-animal 
respiration, separated by mouse strain and diet group 
 
  C57Bl/6 129X1 BALB/c DBA/2 FVB/N 
Body weight 
(g) 
LFD 30.3±0.4 27.6±0.4 26.0±0.6 31.2±0.7 31.1±0.5 
HFD 35.4±0.9 ‡ 34.7±0.6 ‡ 27.8±0.5 39.0±0.8 ‡ 34.5±0.6 ‡ 
Fat mass  
(%) 
LFD 15.6±1.1 22.2±1.9 20.6±0.4 23.7±0.8 18.3±1.2 
HFD 29.4±1.3 ‡ 36.6±2.7 ‡ 29.2±1.3 ‡ 38.8±1.8 ‡ 30.0±1.4 ‡ 
Tissue weights (g) 
eWAT 
LFD 0.34±0.02 0.33±0.01 0.54±0.02 0.79±0.07 0.39±0.06 
HFD 1.42±0.15 ‡ 1.38±0.05 ‡ 1.09±0.10 ‡ 1.82±0.10 ‡ 1.17±0.06 ‡ 
iWAT 
LFD 0.24±0.01 0.34±0.04 0.36±0.04 0.56±0.06 0.33±0.03 
HFD 0.74±0.14 ‡ 0.94±0.07 ‡ 0.54±0.03 † 1.55±0.11 ‡ 0.63±0.03 ‡ 
BAT 
LFD 0.12±0.01 0.12±0.01 0.15±0.03 0.17±0.01 0.17±0.02 
HFD 0.13±0.01 0.21±0.02 † 0.15±0.01 0.34±0.04 ‡ 0.23±0.01 † 
Liver 
LFD 1.48±0.07 1.20±0.02 1.31±0.05 1.63±0.05 1.70±0.04 
HFD 1.21±0.08 1.25±0.07 1.17±0.02 * 1.64±0.04 1.71±0.04 
Food Intake 
 (kcal/day) 
LFD 13.73±0.55 11.31±0.01 12.82±1.18 11.26±0.57 13.69±2.50 
HFD 14.17±1.20 18.00±2.71 * 12.89±0.23 16.10±2.28 * 13.65±0.50 
Whole-body respiration 
(ml O2/g/h) 
LFD 4.27±0.08 4.46±0.15 4.71±0.10 4.63±0.09 4.19±0.10 
HFD 4.86±0.13 † 5.14±0.12 † 5.23±0.09 † 5.16±0.17 * 4.88±0.17 † 
RER 
LFD 0.97±0.03 0.94±0.01 0.97±0.02 0.88±0.02 0.95±0.01 
HFD 0.84±0.01 † 0.87±0.01 * 0.86±0.03 ‡ 0.83±0.01 0.84±0.02 ‡ 
LFD vs. HFD: * p<0.05, † p<0.01 and ‡ p<0.001, n=6-8 for each strain and diet group; 
whole-animal oxygen consumption is corrected for lean mass; BAT = brown adipose tissue; 
eWAT = epididymal white adipose tissue; HFD = high-fat diet; iWAT = inguinal white 




Table 2: Plasma characteristics 
 
  C57Bl/6 129X1 BALB/c DBA/2 FVB/N 
Glucose 
(mM) 
LFD 9.14±0.36 6.59±0.28 7.96±0.34 8.21±0.36 9.67±0.36 
HFD 10.51±0.29† 7.31±0.25 7.74±0.16 9.90±0.50* 10.95±0.43*  
Insulin 
(ng/ml) 
LFD 0.72±0.04 0.54±0.05 0.63±0.06 1.32±0.11 0.90±0.05 
HFD 1.26±0.14† 1.08±0.09‡ 0.64±0.05 2.41±0.32† 1.19±0.08* 
Adiponectin 
(μg/ml) 
LFD 3.84±0.36 4.17±0.36 3.99±0.47 10.24±1.00 7.59±1.02 
HFD 3.59±0.50 4.62±0.48 3.97±0.35 9.45±0.54 7.48±0.42 
TAG 
(μmol/ml) 
LFD 4.39±0.34 5.84±0.17 6.13±0.44 10.76±0.82 10.14±0.92 
HFD 4.52±0.27 7.22±0.40† 6.82±0.42 13.20±1.03 6.57±0.70* 
NEFA 
(μmol/ml) 
LFD 0.76±0.05 0.87±0.05 0.79±0.05 0.97±0.10 0.71±0.04 
HFD 0.79±0.02 0.85±0.08 0.85±0.06 1.01±0.08 0.66±0.04 
LFD vs. HFD: * when p<0.05, † when p<0.01 and ‡ when p<0.001, n=8 for each strain and diet group; HFD = 

















Figure 1: Body weight during the 8-week feeding period (A) and intraperitoneal glucose 
tolerance test (B) in low-fat (LF) and high-fat (HF) fed mice. Glucose (2g/kg) was injected at 
the 0 time point and blood glucose levels were monitored for 90min post-injection. black dots 
= LF mice, white dots = HF mice; end point body weight p<0.0001 for BL6, 129X1, DBA/2 
and FVB/N; n = 6-8 for each strain and diet group.  
Figure 2: Muscle (A) and Liver (B) triglyceride levels in low-fat (LF) and high-fat (HF) fed 
mice; white bars = LF mice, black bars = HF mice; † p<0.01, ‡ p<0.001; n = 6-8 for each 
strain and diet group.  
Figure 3: Markers of mitochondrial oxidative metabolism in skeletal muscle. (A) 
Representative immunoblotting results on muscle oxidative proteins in low-fat (LF) and high-
fat (HF) fed mice. Shown is n=2, but percentage differences underneath the corresponding 
lanes represent n=6-8 for each strain and diet group. Only significant (p<0.05) differences 
between the diet groups are shown. Complex I-V represent subunits of the complexes of the 
ETC chain. Skeletal actin in muscle was used as loading control and shows similar 
distribution between LF- and HF- groups in each strain. (B and C) citrate synthase  and β-
hydroxyacyl CoA dehydrogenase (βHAD) activity in low-fat (LF) and high-fat (HF) fed 
mice; white bars = LF mice, black bars = HF mice; * p<0.05, † p<0.01; n = 6-8 for each 
strain and diet group. 
Figure 4: Markers of oxidative metabolism, lipid synthesis and lipid uptake in the liver. 
Representative immunoblotting results on oxidative and lipogenic enzymes and fatty acid 
transporters in low-fat (LF) and high-fat (HF) fed mice. Shown is n=2, but percentage 
differences underneath the corresponding lanes represent n=6-8 for each strain and diet 
group. Only significant (p<0.05) differences between the diet groups are shown. 14-3-3 was 
used as loading control and shows similar distribution between LF- and HF- groups in each 
strain. 
Figure 5: Inflammation in adipose tissue. Gene expression analysis of (A) F4/80, (B) CD68 
and (C) CD11c+, (D) TNFα, (E) MCP-1 and (F) IL-6 in epididymal adipose tissue of low-fat 
(LF) and high-fat (HF) fed mice; white bars = LF mice, black bars = HF mice; * p<0.05, † 
p<0.01, ‡ p<0.001; n = 5 for each strain and diet group.  
Figure 6: Markers of lipid peroxidative damage in muscle and liver. Lipid hydroperoxides 
(LOOH) (A and C) and TBARS (B and D) were measured in low-fat (LF) and high-fat (HF) 
fed mice as marker of oxidative stress; white bars = LF mice, black bars = HF mice; * 
p<0.05, † p<0.01; n = 6-8 for each strain and diet group.  
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